Welcome to our dedicated page for Anika Therapeutics news (Ticker: ANIK), a resource for investors and traders seeking the latest updates and insights on Anika Therapeutics stock.
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global joint preservation company focused on early intervention orthopedics, osteoarthritis (OA) pain management, and regenerative solutions based on hyaluronic acid and implant technologies. This news page aggregates company-issued updates and market-moving announcements so readers can follow how Anika’s clinical programs, product portfolio, and financial performance evolve over time.
News about Anika commonly covers quarterly and annual financial results, including performance in its Commercial Channel and OEM Channel, as well as commentary on operating expenses, cost-saving measures, and capital allocation decisions such as share repurchase programs. Investors can also find updates on governance and compensation topics, including amendments to equity incentive plans and inducement grants made under Nasdaq Listing Rule 5635(c)(4).
A significant portion of Anika’s news flow focuses on clinical and regulatory milestones for its key products. Examples include updates on the U.S. pivotal Phase III FastTRACK study for the Hyalofast cartilage repair scaffold, the filing of the third and final PMA module for Hyalofast with the U.S. Food and Drug Administration, and progress toward a U.S. New Drug Application for Cingal, the company’s non-opioid, single-injection OA pain management product. Releases also describe commercial milestones, such as Cingal surpassing one million injections worldwide and the growth trajectory of the Integrity Implant System.
Corporate and leadership developments are another recurring theme. Anika issues press releases on planned leadership transitions, board changes, and strategic refocusing around its hyaluronic acid portfolio and regenerative solutions. By reviewing the ANIK news stream on this page, readers can monitor how clinical data, regulatory submissions, commercial performance, and governance actions shape the company’s position in osteoarthritis pain management and orthopedic regenerative medicine.
Anika Therapeutics, Inc. (NASDAQ: ANIK) announced plans to release its Q2 2022 financial results after the market close on August 3, 2022. The company will also hold an investor conference call at 5:00 p.m. ET on the same day to discuss financial results and business highlights. Investors can access the call by dialing 1-888-220-8474 or via a live audio webcast available on Anika's website. The company specializes in joint preservation and minimally invasive orthopedic solutions, focusing on osteoarthritis management and sports medicine.
On June 10, 2022, Anika Therapeutics (NASDAQ: ANIK) announced participation in the Sidoti Small Cap Virtual Investor Conference on June 15, 2022. The management will host a virtual presentation with a Q&A session starting at 11:30 am ET. Investors can access the webcast through the Investor Relations section of Anika's website and an archived version will also be available later. Anika focuses on joint preservation and offers innovative solutions in early intervention orthopedics, including products for osteoarthritis pain management.
Anika Therapeutics announced FDA clearance for its X-Twist Knotless Fixation System, enhancing its offerings for rotator cuff repairs and other orthopedic procedures. The system's design allows for versatile knotless fixation, suitable for various soft tissue applications. Anika plans to begin commercialization in the second half of 2022, targeting the growing market of nearly 670,000 rotator cuff procedures performed in 2021. This clearance positions Anika favorably within the ambulatory surgery center market, aiming for accelerated growth in its Sports Medicine segment.
Anika Therapeutics (NASDAQ: ANIK) announced on May 2, 2022, the granting of stock options and restricted stock units (RSUs) to five newly hired non-executive employees. A total of 13,091 options were granted at an exercise price of $21.61, and 16,113 options at $23.77, which is 110% of the closing price on the grant date. The RSUs covered 20,818 shares. These grants are part of the 2021 Inducement Plan and serve as incentives for employment. Vesting for both options and RSUs occurs over three years, contingent on continuous service to the company.
On May 9, 2022, Anika Therapeutics (NASDAQ: ANIK) announced its participation in the UBS Global Healthcare Conference 2022. The event will take place in-person on May 25, 2022, at the Lotte New York Palace, New York, NY. Anika's management will host a live presentation featuring a fireside chat, starting at 11:30 AM ET. Additionally, they will engage in one-on-one investor meetings on the same day. The presentation will be accessible via a webcast on Anika’s Investor Relations page, with an archive available post-event.
Anika Therapeutics reported a 7% increase in Q1 2022 revenue, reaching $36.7 million, primarily driven by improved order timing in OA Pain Management.
OA Pain Management revenue surged 18% to $22.7 million, while Joint Preservation and Restoration dipped 1% and Non-Orthopedic revenue fell 34%.
The company faced a net loss of $2.9 million, starkly contrasting with a net income of $2.8 million in Q1 2021. Adjusted EBITDA was $2.6 million, down from $4.8 million.
Anika anticipates revenue growth in FY 2022, mainly from Joint Preservation and Restoration, but expects Non-Orthopedic revenue to decline by approximately 20%.
Anika Therapeutics, a joint preservation company, announced the grant of stock options and restricted stock units to three new non-executive employees on April 1, 2022. A total of 10,662 stock options and 5,024 RSUs were awarded under the 2021 Inducement Plan, approved by the compensation committee. The options have an exercise price of $25.50, aligning with the stock's closing price on the grant date. Vesting occurs in equal installments over three years, contingent on continuous service. These grants do not require shareholder approval.
Anika Therapeutics (NASDAQ: ANIK) will release its Q1 2022 financial results on May 5, 2022, after market close. The company will host an investor conference call at 5:00 p.m. ET to discuss the financial outcomes and notable business developments. Interested participants can join the call by dialing the provided numbers and using conference ID 2795291. A live audio webcast and accompanying presentation will be accessible on Anika's website, with recordings available post-call.
Anika Therapeutics (NASDAQ: ANIK) announced management participation in the 21st Annual Needham Virtual Healthcare Conference on April 14, 2022, with a live presentation at 8:00 AM ET. The conference will include 1x1 investor meetings. A webcast of the event can be accessed via Anika’s Investor Relations section on their website, with replays and presentation slides available post-event. Anika focuses on early intervention orthopedic care, targeting osteoarthritis pain management and joint preservation technologies.
Anika Therapeutics (NASDAQ: ANIK) showcased its joint preservation portfolio at the 2022 AAOS Annual Meeting in Chicago from March 23-25. Key products highlighted include the OVOMotion® with Inlay Glenoid Total Shoulder Arthroplasty (TSA) System and Tactoset® Injectable Bone Substitute. CEO Cheryl R. Blanchard emphasized ongoing market interest and plans for future product introductions. The OVOMotion® system offers significant clinical advantages, while Tactoset® enhances surgical efficiency. The company aims to lead advancements in orthopedic care and has launched a redesigned website for comprehensive product information.